Clovis Oncology Inc. (CLVS)

47.04
0.61 1.31
NASDAQ : Health Technology
Prev Close 46.43
Open 46.20
Day Low/High 45.85 / 47.62
52 Wk Low/High 41.31 / 99.45
Volume 527.17K
Avg Volume 1.15M
Exchange NASDAQ
Shares Outstanding 52.55M
Market Cap 2.45B
EPS -7.40
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Clovis Oncology To Present At The Goldman Sachs 39th Annual Global Healthcare Conference 2018

Clovis Oncology To Present At The Goldman Sachs 39th Annual Global Healthcare Conference 2018

Clovis Oncology, Inc. (Nasdaq: CLVS) today announced that Patrick J.

Clovis Oncology Submits Application To EMA To Expand Use Of Rubraca®▼ (rucaparib) To Include Maintenance Treatment For Women With Recurrent Ovarian Cancer

Clovis Oncology Submits Application To EMA To Expand Use Of Rubraca®▼ (rucaparib) To Include Maintenance Treatment For Women With Recurrent Ovarian Cancer

Clovis Oncology, Inc. (NASDAQ: CLVS) today announced the submission of a regulatory application to the European Medicines Agency (EMA), as part of a type II variation seeking to expand the marketing authorization for Rubraca (rucaparib) to include...

Groupon, Applied Materials, Adobe Systems: 'Mad Money' Lightning Round

Groupon, Applied Materials, Adobe Systems: 'Mad Money' Lightning Round

Jim Cramer weighs in on Groupon, Applied Materials, Adobe Systems, Cara Therapeutics, Watsco, CBRL Group, Pilgrim's Pride and more.

Get Used to Uncertainty: Cramer's 'Mad Money' Recap (Tuesday 5/29/18)

Get Used to Uncertainty: Cramer's 'Mad Money' Recap (Tuesday 5/29/18)

Global uncertainty, interest rates, and profit-taking are weighing on the markets. But Jim Cramer argues these events are good for the U.S.

Clovis Oncology Announces European Commission Authorization Of Rubraca® (rucaparib) For Women With Recurrent Ovarian Cancer

Clovis Oncology Announces European Commission Authorization Of Rubraca® (rucaparib) For Women With Recurrent Ovarian Cancer

Clovis Oncology, Inc. (NASDAQ: CLVS) today announced that the European Commission (EC) has authorized Rubraca (rucaparib) as monotherapy treatment of adult patients with platinum-sensitive, relapsed or progressive, BRCA mutated (germline and/or somatic),...

Clovis Oncology Announces Presentations At 2018 ASCO Annual Meeting

Clovis Oncology Announces Presentations At 2018 ASCO Annual Meeting

Clovis Oncology, Inc. (NASDAQ: CLVS) today announced that seven abstracts highlighting progress in the Rubraca preclinical research and clinical development program will be presented at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting...

4 Names to Buy in a Refreshed Biotech Space

4 Names to Buy in a Refreshed Biotech Space

After a strong week for the biotech sector, these names have potential catalysts to move shares.

CORRECTING And REPLACING Clovis Oncology To Present At The Bank Of America Merrill Lynch Healthcare Conference 2018

CORRECTING And REPLACING Clovis Oncology To Present At The Bank Of America Merrill Lynch Healthcare Conference 2018

Presentation and webcast time listed in first paragraph of release should read: Wednesday, May 16, 2018 at 11:20 AM local time (instead of Thursday, May 17, 2018 at 10:00 AM Pacific Time).

Clovis Oncology Announces First Quarter 2018 Operating Results

Clovis Oncology Announces First Quarter 2018 Operating Results

Clovis Oncology, Inc. (NASDAQ:CLVS) reported financial results for the quarter ended March 31, 2018, and provided an update on the Company's clinical development programs and regulatory and commercial outlook for 2018.

Two Oncology Stocks I Like Now

Two Oncology Stocks I Like Now

M&A activity should pick up in the biotech space.

Clovis Oncology To Announce First Quarter 2018 Financial Results And Host Webcast Conference Call On May 8

Clovis Oncology To Announce First Quarter 2018 Financial Results And Host Webcast Conference Call On May 8

Clovis Oncology, Inc. (NASDAQ: CLVS) will announce its first quarter 2018 financial results on Tuesday, May 8, 2018, after the close of the U.

Some Biotech Stocks to Add Exposure To

Some Biotech Stocks to Add Exposure To

Secondary offerings create buying opportunities.

3 Potential Biotech Buyout Targets in the Second Quarter

3 Potential Biotech Buyout Targets in the Second Quarter

Novartis' deal for AveXis has ignited a rally in other gene-therapy concerns.

Possible Biotech Takeout Plays

Possible Biotech Takeout Plays

A look at possible second-quarter M&A activity in the biotech sector.

Infographic: Understanding Ovarian Cancer (Graphic: Business Wire)

Infographic: Understanding Ovarian Cancer (Graphic: Business Wire)

Clovis Oncology, Inc. (NASDAQ:CLVS) today announced that the U.

Ratings Changes Today

TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,100 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: GSM, RSPP, SVM, TDS Downgrades: AG, BGS, DJCO, EVC, GLRE, TCP Initiations: CLVS Read on to get TheStreet Quant Ratings' detailed report:

Clovis Oncology Initiates Early Access Program For Rucaparib As Treatment And As Maintenance Therapy In Recurrent Ovarian Cancer In Europe

Clovis Oncology Initiates Early Access Program For Rucaparib As Treatment And As Maintenance Therapy In Recurrent Ovarian Cancer In Europe

Clovis Oncology, Inc. (NASDAQ:CLVS) today announced the initiation of an early access program in Europe for rucaparib for treatment and as maintenance therapy in recurrent ovarian cancer.

CHMP Grants Positive Opinion For Clovis Oncology's Rubraca® (rucaparib) Tablets

CHMP Grants Positive Opinion For Clovis Oncology's Rubraca® (rucaparib) Tablets

Clovis Oncology, Inc. (NASDAQ: CLVS) today announced that the European Union's (EU) European Medicines Agency (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending the...

Which Hot Biotech Name Will Be Acquired Next?

Which Hot Biotech Name Will Be Acquired Next?

Your burning biotech questions answered in our latest mailbag.

Bret Jensen's Biotech Mailbag

Bret Jensen's Biotech Mailbag

We'll answer two of the common questions we have received so far in March.

Clovis Oncology Announces Notice Of Allowance For Rucaparib High Dosage Strength Tablet Patent With Expiration In 2035

Clovis Oncology Announces Notice Of Allowance For Rucaparib High Dosage Strength Tablet Patent With Expiration In 2035

Clovis Oncology, Inc. (NASDAQ:CLVS) announced today that the Company has received a Notice of Allowance from the United States Patent and Trademark Office in United States Patent Application 14/828,065 with claims...

Clovis Oncology To Present At The Barclays Global Healthcare Conference

Clovis Oncology To Present At The Barclays Global Healthcare Conference

Clovis Oncology, Inc. (Nasdaq: CLVS) today announced that Patrick J.

Clovis Oncology Announces 2017 Operating Results

Clovis Oncology Announces 2017 Operating Results

Clovis Oncology, Inc. (NASDAQ:CLVS) reported financial results for the quarter and year ended December 31, 2017, and provided an update on the Company's clinical development programs and regulatory and commercial...

Clovis Oncology Receives Positive Trend Vote From CHMP In European Regulatory Review For Rucaparib Ovarian Cancer Treatment Indication

Clovis Oncology Receives Positive Trend Vote From CHMP In European Regulatory Review For Rucaparib Ovarian Cancer Treatment Indication

Clovis Oncology, Inc. (NASDAQ: CLVS) announced today an update to the ongoing regulatory review for the Marketing Authorization Application (MAA) for rucaparib tablets as monotherapy for the treatment of a limited...

Clovis Oncology To Announce Fourth Quarter And Full Year 2017 Financial Results And Host Webcast Conference Call On February 26

Clovis Oncology To Announce Fourth Quarter And Full Year 2017 Financial Results And Host Webcast Conference Call On February 26

Clovis Oncology, Inc. (NASDAQ: CLVS) will announce its fourth quarter and full year 2017 financial results on Monday, February 26, 2018, after the close of the U.

Five Rules for This Market Beast: Cramer's 'Mad Money' Recap (Tues 1/16/18)

Five Rules for This Market Beast: Cramer's 'Mad Money' Recap (Tues 1/16/18)

Even with Monday's sharp reversal, Jim Cramer says he still likes this market.

Clovis Oncology To Present At The 36th Annual J.P. Morgan Healthcare Conference

Clovis Oncology To Present At The 36th Annual J.P. Morgan Healthcare Conference

Clovis Oncology, Inc. (Nasdaq: CLVS) today announced that its Chief Executive Officer and President, Patrick J.

Rucaparib MAA For The Ovarian Cancer Treatment Indication Referred By CHMP To Scientific Advisory Group On Oncology For Review Expected In February 2018

Rucaparib MAA For The Ovarian Cancer Treatment Indication Referred By CHMP To Scientific Advisory Group On Oncology For Review Expected In February 2018

Clovis Oncology, Inc. (NASDAQ: CLVS) announced today that the European Union's (EU) European Medicines Agency (EMA) Committee for Medicinal Products for Human Use (CHMP) has requested that the Scientific Advisory Group...

TheStreet Quant Rating: D- (Sell)